Analysts Set Hinge Health Inc. (NYSE:HNGE) Target Price at $67.40

Hinge Health Inc. (NYSE:HNGE) has been given an average recommendation of “Moderate Buy” by the twenty analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, sixteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $67.5333.

Several research firms recently weighed in on HNGE. Barclays raised their price objective on Hinge Health from $52.00 to $62.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price objective on shares of Hinge Health in a research note on Wednesday, May 6th. Truist Financial set a $79.00 price objective on Hinge Health in a research note on Wednesday, May 6th. Citigroup reaffirmed an “outperform” rating on shares of Hinge Health in a research note on Wednesday, May 6th. Finally, Wells Fargo & Company raised their price objective on Hinge Health from $68.00 to $80.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th.

Insiders Place Their Bets

In other news, President James Pursley sold 16,000 shares of Hinge Health stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $53.79, for a total transaction of $860,640.00. Following the sale, the president directly owned 780,223 shares of the company’s stock, valued at approximately $41,968,195.17. This trade represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Budge sold 5,907 shares of Hinge Health stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $53.79, for a total value of $317,737.53. Following the sale, the chief financial officer directly owned 445,386 shares in the company, valued at $23,957,312.94. The trade was a 1.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 554,600 shares of company stock valued at $29,859,068. 18.92% of the stock is owned by corporate insiders.

Institutional Trading of Hinge Health

A number of hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in shares of Hinge Health by 35.2% during the first quarter. California State Teachers Retirement System now owns 19,141 shares of the company’s stock valued at $738,000 after purchasing an additional 4,986 shares in the last quarter. Estuary Capital Management LP acquired a new stake in shares of Hinge Health during the first quarter valued at about $15,201,000. Lazard Asset Management LLC boosted its stake in shares of Hinge Health by 0.6% during the first quarter. Lazard Asset Management LLC now owns 63,705 shares of the company’s stock valued at $2,456,000 after purchasing an additional 386 shares in the last quarter. Entropy Technologies LP boosted its stake in shares of Hinge Health by 28.1% during the first quarter. Entropy Technologies LP now owns 11,749 shares of the company’s stock valued at $453,000 after purchasing an additional 2,579 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Hinge Health by 225.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock valued at $44,852,000 after purchasing an additional 806,007 shares in the last quarter.

Hinge Health Stock Performance

Shares of NYSE HNGE opened at $63.48 on Monday. Hinge Health has a 52 week low of $30.08 and a 52 week high of $66.55. The stock has a market capitalization of $4.91 billion and a P/E ratio of -5.14. The stock’s fifty day moving average is $47.93 and its 200 day moving average is $45.31.

Hinge Health (NYSE:HNGE) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.33. The business had revenue of $182.31 million for the quarter. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The business’s quarterly revenue was up 47.2% compared to the same quarter last year. During the same period last year, the business earned $1.30 earnings per share. Equities research analysts forecast that Hinge Health will post 1.21 earnings per share for the current year.

Key Stories Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Hinge Health to $65 from $63 and reiterated a buy rating, reinforcing a constructive analyst view on the stock. Article Title
• Positive Sentiment: Other recent commentary also stayed upbeat, including technical coverage pointing to a “golden cross,” which can attract momentum investors. Article Title
• Positive Sentiment: Hinge Health’s last earnings report beat estimates, with revenue up 47.2% year over year, supporting the view that the business is still growing rapidly. Article Title
• Neutral Sentiment: One article highlighted Hinge Health as a promising mid-cap healthcare name, but it did not include a new catalyst beyond a generally favorable long-term investment case. Article Title
• Negative Sentiment: Chairman Gabriel M.I. Mecklenburg disclosed another large insider sale of 50,000 shares at $65.54, adding to a series of recent sales and potentially creating some overhang for sentiment. Article Title

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.